久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國Alexion Pharmaceuticals
Alexion制藥公司是一家生物制藥企業，致力于為罹患重癥致命疾病的患者開發生產救命藥物。Alexion公司從事治療藥物的探索、開發和推廣，這些藥物用于治療種類廣泛的嚴重疾病，包括血液系統和腎臟疾病、移植、癌癥和自身免疫疾病。Soliris是Alexion公司首個上市的藥物。Alexion公司正在評估Soliris治療其他適應證的可能性、以及依庫珠單抗其他劑型治療附加臨床適應證的可能性，其他處于早期開發階段的抗體備選產品也正在開發中。

Alexion is a global biopharmaceutical company that combines groundbreaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris? (eculizumab), a first-in-class terminal complement inhibitor approved in the United States, European Union, Canada and Australia as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion is working urgently to investigate Soliris and additional biopharmaceuticals as treatments for patients with other rare and severe diseases, including cancer.